Study to Investigate the Performance of Cervical Arthroplasty for the Treatment of Cervical Degenerative Disc Disease

This study has been terminated.
(study progress and recruitment rate too low)
Sponsor:
Information provided by (Responsible Party):
DePuy International
ClinicalTrials.gov Identifier:
NCT00700739
First received: June 18, 2008
Last updated: September 2, 2015
Last verified: September 2015
  Purpose
The purpose of the study is to evaluate the performance of the Discover cervical Artificial disc in the treatment of degenerative disc disease in one level of the cervical spine.

Condition Intervention Phase
Cervical Degenerative Disc Disease
Device: DISCOVER™ Artificial Cervical Disc
Device: ACDF
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Multi-Centre, Prospective, Randomized, Post Marketing Surveillance Study Comparing Cervical Arthroplasty to Anterior Cervical Discectomy and Fusion (ACDF) for the Treatment of Cervical Degenerative Disc Disease

Further study details as provided by DePuy International:

Primary Outcome Measures:
  • Overall Patient Success [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
    Overall success was a composite endpoint determined by the following clinical outcome measures: 1. Neck Disability Index ≥ 15-point improvement from baseline to 12 months post-operative, 2. No new clinically significant permanent abnormalities in neurological function (i.e. motor strength, nerve root tension signs, sensory and reflex signs) from baseline to 12 months post-operative, 3. No subsequent secondary surgical interventions (SSI) at the index level, and 4. No device-related serious events (dSAE) from intra-operative through 12-months post-operative. Please note that these time periods were intended to be from baseline to 24 months post-operative, but since the study was terminated early the 12 month time periods were utilized.


Secondary Outcome Measures:
  • Change in Visual Analogue Scale (VAS) Neck Pain From Pre-treatment to 12 Months [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    The visual analogue scale (VAS) pain score asks the subject to place a vertical mark on a horizontal line (that is approximately 10 cm long) with 'No Pain' (score of 0 = 0 cm) listed on the left and 'Very severe pain' (score of 100 = 10 cm) labeled on the right. The subject is instructed to indicate the amount of pain they feel in their neck.

  • Change in Visual Analogue Scale (VAS) Left Arm Pain From Pre-treatment to 12 Months. [ Time Frame: 12 Months ] [ Designated as safety issue: No ]
    The visual analogue scale (VAS) pain score asks the subject to place a vertical mark on a horizontal line (that is approximately 10 cm long) with 'No Pain' (score of 0 = 0 cm) listed on the left and 'Very severe pain' (score of 100 = 10 cm) labeled on the right. The subject is instructed to indicate the amount of pain they feel in their left arm.

  • Change in Visual Analogue Scale (VAS) Right Arm Pain From Pre-treatment to 12 Months. [ Time Frame: 12 Months ] [ Designated as safety issue: No ]
    The visual analogue scale (VAS) pain score asks the subject to place a vertical mark on a horizontal line (that is approximately 10 cm long) with 'No Pain' (score of 0= 0 cm) listed on the left and 'Very severe pain' (score of 100= 10 cm) labeled on the right. The subject is instructed to indicate the amount of pain they feel in their right arm.

  • Change in Visual Analogue Scale (VAS) Right Shoulder Pain From Pre-treatment to 12 Months. [ Time Frame: 12 Months ] [ Designated as safety issue: No ]
    The visual analogue scale (VAS) pain score asks the subject to place a vertical mark on a horizontal line (that is approximately 10 cm long) with 'No Pain' (score of 0 = 0 cm) listed on the left and 'Very severe pain' (score of 100 = 10 cm) labeled on the right. The subject is instructed to indicate the amount of pain they feel in their right shoulder.

  • Change in Visual Analogue Scale (VAS) Left Shoulder Pain From Pre-treatment to 12 Months. [ Time Frame: 12 Months ] [ Designated as safety issue: No ]
    The visual analogue scale (VAS) pain score asks the subject to place a vertical mark on a horizontal line (that is approximately 10 cm long) with 'No Pain' (score of 0 = 0 cm) listed on the left and 'Very severe pain' (score of 10 = 10 cm) labeled on the right. The subject is instructed to indicate the amount of pain they feel in their left shoulder.

  • Change in Mental Component Summary Quality of Life Measure Assessed by Short Form SF-36 From Pre-treatment to 12 Months [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    The 36-item Short Form Health Survey (SF-36) is a patient reported outcome survey that evaluates functional health and well-being. The survey is converted into 2 summary measures that are scored from 0 to 100 (where 100 indicates the highest level of health) - the Physical Component Score (PCS-36) and Mental Component Score (MCS-36)

  • Change in Physical Component Summary Quality of Life Measure Assessed by Short Form SF-36 From Pre-treatment to 12 Months [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    The 36-item Short Form Health Survey (SF-36) is a patient reported outcome survey that evaluates functional health and well-being. The survey is converted into 2 summary measures that are scored from 0 to 100 (where 100 indicates the highest level of health) - the Physical Component Score (PCS-36) and Mental Component Score (MCS-36)

  • Change in Function Assessed by Neck Disability Index Improvement From Pre-treatment to 12 Months [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    The neck disability index (NDI) is a validated, disease specific, self-administrated questionnaire for assessing pain intensity and function in patients with neck pain on a scale from 0 to 100. A lower score is a better result (i.e. less severe pain and/or better function). The proportion of patients with an improved score (lower) of 15 points or more was the analysis variable.

  • Work Status Assessed at 12 Months [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    The proportion of subjects with unrestricted work status (compared to subjects not working or with restricted work status) is reported at the 12 month follow-up interval.

  • Sagittal Angulation, Also Known as Global Lordosis, Measured Radiographically at 6 Months [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    Sagittal Angulation is a measure of the angle formed between the inferior endplate of the C2 vertebrae and the corresponding inferior endplate of vertebrae C7 of the spine, measured in degrees, from a side (sagittal) view.

  • Adjacent Level Degeneration Measured Radiographically at 24 Months [ Time Frame: 24 months ] [ Designated as safety issue: No ]
    Adjacent Level Degeneration is evaluated using a point system that assigns numerical scores to severity of Height Loss, Anterior Osteophytes, and Endplate Sclerosis; and then grades into one of the following five categories: None, Mild, Moderate, Severe, or NA.

  • Maintenance of Disc Height Measured Radiographically at 6 Months [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    Maintenance of disc height is measured at the index and adjacent levels to determine the effect of the treatment on restoration or maintenance of the disc height. Initial post-operative disc height is compared with subsequent post-operative visits (i.e. 6 months) to evaluate the maintenance of disc height. The height is measured in millimeters (mm).

  • Foraminal Height Measured Radiographically at 24 Months [ Time Frame: 24 months ] [ Designated as safety issue: No ]
    Foraminal height is the maximum vertical distance, measured in millimeters (mm), between the inferior surface of the superior pedicle and superior surface of the inferior pedicle. These measurements are obtained via magnetic resonance imaging (MRI).

  • Cervical Range of Motion Measured Radiographically at 6 Months [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    Cervical range of motion measures the angle, in degrees, between the inferior endplate of C2 to the inferior endplate of C7 on flexion-extension radiographs.

  • Device Related Adverse Events [ Time Frame: Intra-operatively to 24 months post-operative ] [ Designated as safety issue: Yes ]
    The proportion of subjects with device related adverse events as reported throughout the duration of the study.


Enrollment: 60
Study Start Date: May 2008
Study Completion Date: May 2010
Primary Completion Date: May 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Anterior Cervical Discectomy and Fusion (ACDF)
Anterior Cervical Discectomy and Fusion with Cervical CFRP I/F CAGE® and SLIM LOC(R) Anterior Cervical Plate System with allograft
Device: ACDF
Cervical CFRP I/F CAGE® and SLIM LOC(R) Anterior Cervical Plate System with allograft
Active Comparator: Cervical Total Disc Replacement
DISCOVER™ Artificial Cervical Disc
Device: DISCOVER™ Artificial Cervical Disc
DISCOVER™ Artificial Cervical Disc

Detailed Description:
The protocol underwent 3 amendments, the last of which (02APR2009) changed the study design from a randomized to a non-randomized and non-comparative clinical trial. All of the subjects were enrolled under the randomized design with the exception of the last subject. This study is not applicable per FDAA Title VIII, Section 801 due to the final trial design. However, results are submitted to clinicaltrials.gov due to the majority of study data being collected under a randomized (FDAA Title VIII, Section 801 applicable) trial design
  Eligibility

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female subjects, aged between 18 and 65 years inclusive.
  • Subjects who are able to give voluntary, written informed consent to participate in this clinical investigation and from whom consent has been obtained.
  • Subjects who, in the opinion of the Clinical Investigator, are able to understand this clinical investigation, co-operate with the investigational procedures and are willing to return to the hospital for all the required post-operative follow-ups.
  • Objective evidence of cervical disc disease in one vertebral level between C3-C7 defined as one or more of the following:

    • Shoulder and/or arm pain in a radicular distribution resulting from herniated disc or bony osteophytes (Consistent w diagnostic imaging including Axial CT, CT Myelogram, MRI and/or plain films)
    • Subjects with myeloradiculopathy resulting from mild spinal cord compression and nerve root impingement
  • Unresponsive to documented non-surgical management for ≥ 6 weeks and/or presents with progressive symptoms of nerve root or spinal cord compression in the face of continued non-surgical management (e.g., physical therapy, medication therapy, corticosteroid injections, etc.)
  • Minimum Neck Disability Index score of ≥30 % (15/50 points)

Exclusion Criteria:

  • Subjects who, in the opinion of the Clinical Investigator, have an existing condition that would compromise their participation and follow-up in this clinical investigation.
  • Subjects who are pregnant, lactating or wishes to become pregnant within the duration of the study.
  • Subjects who are known drug or alcohol abusers or with psychological disorders that could affect follow-up care or treatment outcomes.
  • Subjects who have participated in a clinical investigation with an investigational product in the last 30 days.
  • Subjects who are currently involved in any injury litigation claims.
  • Subjects with significant degeneration at more than one cervical level (e.g. DISH, ankylosing spondylitis, congenital abnormality, rheumatoid arthritis)
  • Subjects who have had any prior surgery at the level to be treated (subjects with a prior Laminotomy at the level to be treated may be included in the study)
  • Subjects who have marked cervical instability on lateral or flexion/extension x-rays defined as translation ≥3mm and/or ≥11 degrees of rotational difference to either adjacent level
  • Subjects who have presence of systemic infection or infection at the site of surgery
  • Subjects who have been diagnosed with malignancy
  • Subjects who have been diagnosed with a condition or require postoperative medication(s) that may interfere with bony/soft tissue healing
  • Subjects who have been diagnosed with Osteoporosis, Osteopenia, other metabolic bone disease or endocrine disorder known to affect osteogenesis.
  • Subjects with pre-existing neurological abnormalities other than deficits produced from the spinal lesion (e.g., MS, Parkinson's, CVA, diabetic neuropathy, peripheral neuropathy).
  • Subjects with morbid obesity defined as a BMI of ≥40, or more than 100 lbs (45.4kg) over ideal weight.
  • Subjects with any known allergy to titanium metal, polyethylene, metal alloy or carbon fibre reinforced polymer
  • Subjects who have had prior fusion surgery at any level(s) (C1-T1)
  • Subjects with kyphosis >-15 degrees evaluated using the Cobb angle measurement
  • Subjects with Significant cervical degenerative disease characterized by bridging anterior osteophytes, significant loss of disc space height (3mm or less), sclerotic facets, large posterior osteophytes, autofusion of other cervical levels, and degenerative retrolisthesis. Spinal diseases such as DISH, ankylosing spondylitis, congenital abnormality, and rheumatoid arthritis, should also be excluded
  • Subjects undergoing treatment with a bone growth stimulator, which cannot be discontinued prior to enrollment in the study.
  • Significant kyphotic deformity or significant reversal of lordosis.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00700739

Locations
Australia, New South Wales
Westmead Private Hospital
Sydney, New South Wales, Australia
Australia
Calvary Hospital
Tasmania, Australia
Germany
Klinikum Neustadt
Neustadt, Holstein, Germany
Italy
Divisione di Neurochirurgia
Rome, Italy
Malaysia
Island Hospital
Penang, Malaysia
Netherlands
Elisabeth Ziekenhuis
Tilburg, Netherlands
Spain
La Paz Hospital
Madrid, Spain
United Kingdom
Hope Hospital
Manchester, Lancashire, United Kingdom
Sponsors and Collaborators
DePuy International
  More Information

Responsible Party: DePuy International
ClinicalTrials.gov Identifier: NCT00700739     History of Changes
Other Study ID Numbers: CT 05/25 
Study First Received: June 18, 2008
Results First Received: July 13, 2015
Last Updated: September 2, 2015
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by DePuy International:
Cervical
Disc
Arthroplasty
Spinal

Additional relevant MeSH terms:
Spinal Diseases
Intervertebral Disc Degeneration
Bone Diseases
Musculoskeletal Diseases

ClinicalTrials.gov processed this record on July 26, 2016